Two Sigma Investments LP Has $20.27 Million Position in Bio-Rad Laboratories (NYSE:BIO)

Two Sigma Investments LP lifted its position in shares of Bio-Rad Laboratories (NYSE:BIO) by 64.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 84,915 shares of the medical research company’s stock after buying an additional 33,199 shares during the quarter. Two Sigma Investments LP owned approximately 0.29% of Bio-Rad Laboratories worth $20,267,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its holdings in Bio-Rad Laboratories by 297.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 560 shares of the medical research company’s stock valued at $134,000 after acquiring an additional 419 shares during the last quarter. Timber Hill LLC bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $214,000. Private Advisor Group LLC bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $248,000. Macquarie Group Ltd. bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $255,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Bio-Rad Laboratories by 42.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock valued at $278,000 after acquiring an additional 350 shares during the last quarter. Institutional investors own 64.52% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of analysts have issued reports on the stock. Wells Fargo reduced their price target on shares of Bio-Rad Laboratories from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, February 28th. Jefferies Group lifted their price target on shares of Bio-Rad Laboratories to $325.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Citigroup boosted their target price on shares of Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $291.00 target price on the stock in a report on Wednesday, December 13th. Finally, ValuEngine upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $297.20.

Shares of Bio-Rad Laboratories stock traded down $3.37 during trading hours on Friday, reaching $244.10. The company’s stock had a trading volume of 127,070 shares, compared to its average volume of 128,085. Bio-Rad Laboratories has a one year low of $199.94 and a one year high of $279.59. The company has a quick ratio of 2.75, a current ratio of 3.93 and a debt-to-equity ratio of 0.15. The company has a market cap of $7,365.45, a PE ratio of 59.54, a price-to-earnings-growth ratio of 2.15 and a beta of 0.94.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.22. The firm had revenue of $620.43 million for the quarter, compared to the consensus estimate of $618.89 million. Bio-Rad Laboratories had a net margin of 5.31% and a return on equity of 3.63%. sell-side analysts expect that Bio-Rad Laboratories will post 5.75 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Two Sigma Investments LP Has $20.27 Million Position in Bio-Rad Laboratories (NYSE:BIO)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/two-sigma-investments-lp-purchases-33199-shares-of-bio-rad-laboratories-inc-bio.html.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply